一圖看懂維立志博IPO
維立志博是下一代腫瘤免疫療法的領跑者。成立於2012年,是一家處於臨牀階段的生物科技公司,致力於創新療法的發現、開發及商業化,重點解決PD-1/PD-L1抗體爲代表的現有療法不能治療的疾病,以滿足中國及全球在腫瘤、自身免疫性疾病及其他重大疾病方面未獲滿足的醫療需求。
公司採用科學驅動的研發方法,開發了多個具備一體化、人工智能驅動及多樣化抗體工程能力的專有技術平臺,包括LeadsBody™平臺(CD3 T-Cell Engager平臺)、X-body™平臺(4-1BB Engager平臺)和ADC平臺。這是針對不同靶點、作用機制及藥物類型不斷進行藥物創新的動力源泉。
公司亦成功建立起早期研發、臨牀開發、CMC以及業務拓展方面無縫銜接的自主能力,以自主創新爲基礎,作好充分準備與頭部藥企參與競及風險資本建立戰略合作夥伴關係,加速候選藥物在全球範圍內的臨牀開發及商業上市,充分擴大其變革性療法的影響及覆蓋範圍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.